Drug Trial Radar · NCT02507284
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
Last checked: Nov 19, 2026Latest source record: Jul 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
106
Actual
Start
May 10, 2016
Primary completion
Sep 10, 2018
Study completion Dec 21, 2018
Sponsor
- Lead sponsor
- Azevan PharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- National Institute of Neurological Disorders and Stroke (NINDS); NeuroNEXT Network
- First posted
- Jul 23, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the tolerability, safety and activity of SRX246 in the treatment of irritability in patients with Huntington's disease. Two-thirds of all participants will receive SRX246, while the other third will receive a placebo.
Conditions
- Irritable Mood
- Huntington's Disease
Interventions
SRX246Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Tolerability of SRX246Time frame: 12 weeks
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama
UCLA, Neurology Clinic
Los Angeles, California
UC Davis Medical Center, Department of Neurology, CTSC Clinical Research Center
Sacramento, California
University of Colorado Hospital Translational Research Center
Aurora, Colorado
University of Miami, Miller School of Medicine, Jackson Behavioral Health Hospital
Miami, Florida
Emory University
Atlanta, Georgia
Northwestern Out-Patient Neurology Clinic
Chicago, Illinois
University of Kansas Medical Center
Kansas City, Kansas
Massachusetts General Hospital
Charlestown, Massachusetts
Washington University School of Medicine
St Louis, Missouri
SUNY Stony Brook Clinical Research Center, Department of Neurology
East Setauket, New York
Columbia University Medical Center, New York Presbyterian Hospital
New York, New York
University of Rochester Medical Center
Rochester, New York
University Medical Arts Building
Cincinnati, Ohio
Ohio State University, Wexner Medical Center, Department of Neurology
Columbus, Ohio
Oregon Health and Science University
Portland, Oregon
University of Pittsburgh Medical Center, Department of Neurology
Pittsburgh, Pennsylvania
Vanderbilt Clinical Research Center
Nashville, Tennessee
UT Southwestern Medical Center
Dallas, Texas
University of Utah, Department of Neurology
Salt Lake City, Utah
University of Virginia Health System, Department of Neurology
Charlottesville, Virginia
Swedish Neuroscience Institute
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.